- People
- Offices
- Capabilities
back- Capabilities
- Corporate, Finance and Investments
- back
- Corporate, Finance and Investments
- Overview
- Activist Defense
- Capital Markets
- Construction and Procurement
- Corporate Governance
- Emerging Companies and Venture Capital
- Employee Benefits and Executive Compensation
- Energy and Infrastructure Projects
- Financial Restructuring
- Fund Finance
- Global Human Capital and Compliance
- Investment Funds and Asset Management
- Leveraged Finance
- Mergers and Acquisitions (M&A)
- Middle East and Islamic Finance and Investment
- Private Equity
- Public Companies
- Real Estate
- Structured Finance and Securitization
- Tax
- Technology Transactions
- Government Matters
- back
- Government Matters
- Overview
- Antitrust
- Data, Privacy and Security
- Environmental, Health and Safety
- FDA and Life Sciences
- Government Advocacy and Public Policy
- Government Contracts
- Healthcare
- Innovation Protection
- International Trade
- National Security and Corporate Espionage
- Securities Enforcement and Regulation
- Special Matters and Government Investigations
- Trial and Global Disputes
- back
- Trial and Global Disputes
- Overview
- Antitrust
- Appellate, Constitutional and Administrative Law
- Bankruptcy and Insolvency Litigation
- Class Action Defense
- Commercial Litigation
- Corporate and Securities Litigation
- E-Discovery
- Global Construction and Infrastructure Disputes
- Innovation Protection
- Intellectual Property
- International Arbitration and Litigation
- Labor and Employment
- Product Liability
- Professional Liability
- Toxic & Environmental Torts
- Industries / Issues
- back
- Industries / Issues
- Automotive, Transportation and Mobility
- Energy Transition
- Energy
- Financial Services
- Food and Beverage
- Higher Education
- Life Sciences and Healthcare
- Technology
- Artificial Intelligence (AI) and Machine Learning
- Buy American
- Crisis Management
- Doing Business in Latin America
- Environmental Agenda
- Environmental, Social and Governance (ESG)
- Focus on Women's Health
- Russia/Ukraine
- Special Purpose Acquisition Companies (SPACs)
- Careers
- News & Insights
- About
- Languages
Geneviève Michaux
News 6 results
Recognition
March 19, 2026
Chambers 2026 European Guides Recognize King & Spalding Among Top International Law Firms
In the News · Source: PharmaVoice
Recognition
March 26, 2025
Legal 500 EMEA 2025 Ranks King & Spalding among the Top Firms in Europe, the Middle East and Africa
Recognition
March 20, 2025
Chambers 2025 European Guides Recognize King & Spalding Among Top International Law Firms
Events 20 results
Webinar
April 23, 2026
AI in EU Pharma: Navigating Efficiency, Innovation and Regulatory Challenges
Speaking Engagement
April 2, 2026
Christina Markus and Geneviève Michaux to Speak at two European Cell and Gene Therapy Research Consortia
Webinar
March 12, 2026
Key Revisions of the EU General Pharmaceutical Legislation
Webinar
January 29, 2026
The Revision of the EU General Pharmaceutical Legislation
Insights 15 results
Client Alert
March 9, 2026
EUROPE – Revision of the EU General Pharmaceutical Legislation – Regulatory Protections
Client Alert
December 22, 2025
EUROPE - Major Regulatory Developments in Pharmaceuticals, Biotechnology, and Medical Devices
Article · Source: Financier Worldwide
October 16, 2025
Update to the European rules on advertising medicinal products
Client Alert
July 11, 2025
FDA Publishes More Than 200 Complete Response Letters (CRLs) With More to Come